Title |
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
|
---|---|
Published in |
Arthritis Research & Therapy, July 2014
|
DOI | 10.1186/ar4606 |
Pubmed ID | |
Authors |
Paolo Fraticelli, Barbara Gabrielli, Giovanni Pomponio, Gabriele Valentini, Silvia Bosello, Piersandro Riboldi, Maria Gerosa, Paola Faggioli, Roberto Giacomelli, Nicoletta Del Papa, Roberto Gerli, Claudio Lunardi, Stefano Bombardieri, Walter Malorni, Angelo Corvetta, Gianluca Moroncini, Armando Gabrielli |
Abstract |
Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 1% |
Unknown | 94 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 16 | 17% |
Other | 13 | 14% |
Student > Postgraduate | 10 | 11% |
Student > Bachelor | 9 | 9% |
Student > Master | 7 | 7% |
Other | 15 | 16% |
Unknown | 25 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 46 | 48% |
Agricultural and Biological Sciences | 8 | 8% |
Nursing and Health Professions | 7 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Biochemistry, Genetics and Molecular Biology | 2 | 2% |
Other | 6 | 6% |
Unknown | 24 | 25% |